The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.

The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one ore more oxalate-reducing enzymes to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions.

Disclosed herein are oxalate inducing enzymes with pH and thermal stability and methods of using for oxalate related conditions for in food processing.

The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions.

The disclosure relates generally to bacteria that have been modified to have increased oxalate degrading activity, pharmaceutical compositions including the bacteria, and methods of treating disorders associated with an elevated amount of oxalate, e.g., hyperoxaluria.

The invention includes novel routes of synthesis that involve the use of an acyloin condensation reaction between a ketone and formyl-CoA to form a corresponding branched 2-hydroxyacyl-CoAs and forming branched chain products therefrom. Described are genetically modified microorganisms that produce a branched product from a ketone and formyl-CoA and methods of producing a branched product, including in vivo and in vitro methods.

Provided are systems and methods for converting C1 substrates to products contain more than one carbon, without producing central metabolic building blocks as intermediate products. In an embodiment, system/method can include a biochemical pathway enabling an orthogonal platform for C1 utilization based on formyl-CoA elongation (FORCE) reactions. In an embodiment, the system/method can include acyloin condensations between formyl-CoA and carbonyl-containing molecules. In an embodiment, the system/method can include a reactions catalyzed by the enzyme 2-hydroxyacyl-CoA lyase (HACL).